Clearstead Advisors’s XBiotech XBIT Stock Holding History

Clearstead Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17	Closed	-$51	–	3266
2025 Q2	$51	Buy	+17	New	+$49	﹤0.01%	2667

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Clearstead Advisors's XBIT Position: Q3 2025 in Review

Clearstead Advisors sold out of XBiotech (XBIT) in Q3 2025, closing a stake of 17 shares — an estimated $51 sold.

Clearstead Advisors first reported a position in XBIT in Q2 2025 and held it in 1 quarter. The position peaked at $51 in Q2 2025. 48 funds tracked by Wall St. Rank hold XBIT as of Q3 2025.

Clearstead Advisors reported no remaining XBiotech position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 17 XBiotech shares in Q3 2025, an estimated $51.
Clearstead Advisors first reported a position in XBiotech in Q2 2025 and held it in 1 quarter.
Clearstead Advisors's XBiotech position peaked at $51 in Q2 2025.
48 funds tracked by Wall St. Rank held XBiotech as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.